CADTH | Evidence Driven
CADTH | Evidence Driven

Difluoromethylornithine for the Treatment of Neuroblastoma in the Pediatric Population: Clinical Effectiveness, Cost-Effectiveness, and Guidelines

Details

Files
Project Status:
Completed
Project Line:
Reference List
Project Sub Line:
Reference List
Project Number:
RA0971-000

Question


  1. What is the clinical effectiveness of difluoromethylornithine (DFMO) for the treatment or preventative treatment of neuroblastoma in the pediatric population?

  2. What is the cost-effectiveness of difluoromethylornithine (DFMO) for the treatment or preventative treatment of neuroblastoma in the pediatric population?

  3. What are the evidence-based guidelines associated with the use of difluoromethylornithine (DFMO) for the treatment or preventative treatment of neuroblastoma in the pediatric population?


Key Message

One non-randomized study was identified regarding difluoromethylornithine (DFMO) for the treatment of prevention of neuroblastoma in the pediatric population.


Files

Difluoromethylornithine for the Treatment of Neuroblastoma in the Pediatric Pop… View PDF

Related Content

Last Updated : October 5, 2018